• PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing.
    • Schwartzberg L, Garber JE, Robson ME.
    • National Comprehensive Cancer Network. Continuing Education. 2018 Dec 30.
    • CEU Activity
    • USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    • Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
    • Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
    • Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.
    • Siraj AK, Pratheeshkumar P, Parvathareddy SK, Divya SP, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.
    • Oncotarget. 2018 Dec 18;9(99):37319-37332. doi: 10.18632/oncotarget.26470. eCollection 2018 Dec 18.
    • The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    • Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, Jonkers J, Rottenberg S, Chapman JR.
    • Nat Commun. 2018 Dec 17;9(1):5406. doi: 10.1038/s41467-018-07855-x.
    • Development of PARP and Immune-Checkpoint Inhibitor Combinations.
    • Stewart RA, Pilié PG, Yap TA.
    • Cancer Res. 2018 Dec 15;78(24):6717-6725. doi: 10.1158/0008-5472.CAN-18-2652. Epub 2018 Nov 29.
    • Review
    • Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.
    • Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, Madhusudan S.
    • Cancer Res. 2018 Dec 15;78(24):6818-6827. doi: 10.1158/0008-5472.CAN-18-0633. Epub 2018 Oct 8.
    • Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
    • Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.
    • Clin Cancer Res. 2018 Dec 15;24(24):6459-6470. doi: 10.1158/1078-0432.CCR-17-1118. Epub 2018 Aug 14.
    • Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    • Faraoni I, Graziani G.
    • Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487.
    • Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    • Haynes B, Murai J, Lee JM.
    • Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
    • Review
    • Emerging ways to treat breast cancer: will promises be met?
    • Samadi P, Saki S, Dermani FK, Pourjafar M, Saidijam M.
    • Cell Oncol (Dordr). 2018 Dec;41(6):605-621. doi: 10.1007/s13402-018-0409-1. Epub 2018 Sep 27.
    • Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
    • Gleeson FC, Levy MJ.
    • Curr Treat Options Gastroenterol. 2018 Dec;16(4):441-448. doi: 10.1007/s11938-018-0195-x.
    • Review
    • Talazoparib: First Global Approval.
    • Hoy SM.
    • Drugs. 2018 Dec;78(18):1939-1946. doi: 10.1007/s40265-018-1026-z.
    • Review
    • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    • Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.
    • Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
    • Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S.
    • Int J Nanomedicine. 2018 Nov 29;13:8063-8074. doi: 10.2147/IJN.S186881. eCollection 2018.
    • Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
    • Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.
    • J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4.
    • Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    • Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S.
    • Bioconjug Chem. 2018 Nov 21;29(11):3817-3832. doi: 10.1021/acs.bioconjchem.8b00667. Epub 2018 Oct 25.
    • Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast.
    • Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M.
    • Oncotarget. 2018 Nov 20;9(91):36379-36391. doi: 10.18632/oncotarget.26372. eCollection 2018 Nov 20.
    • Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    • Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES.
    • PLoS One. 2018 Nov 16;13(11):e0207399. doi: 10.1371/journal.pone.0207399. eCollection 2018.
    • Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
    • Póti Á, Berta K, Xiao Y, Pipek O, Klus GT, Ried T, Csabai I, Wilcoxen K, Mikule K, Szallasi Z, Szüts D.
    • Br J Cancer. 2018 Nov 14. doi: 10.1038/s41416-018-0312-6. [Epub ahead of print]
    • Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
    • Pearre DC, Tewari KS.
    • Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018.
    • Pricey Precision Medicine Often Financially Toxic For Cancer Patients.
    • Szabo L.
    • Kaiser Health News. 2018 Nov 1.

    Research News: The cost of cancer care and impact of financial hardship on treatment. (FORCE XRAYS)

    • PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
    • Sharif-Askari B, Amrein L, Aloyz R, Panasci L.
    • Breast Cancer Res Treat. 2018 Nov;172(1):23-32. doi: 10.1007/s10549-018-4888-6. Epub 2018 Jul 23.
    • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    • Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.
    • Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.
    • Mechanisms of PARP inhibitor sensitivity and resistance.
    • D'Andrea AD.
    • DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.
    • A Case of Immune-Mediated Liver Injury Induced by Olaparib.
    • Tufoni M, Serena Ricci C, Zaccherini G.
    • Hepatology. 2018 Nov;68(5):2039-2041. doi: 10.1002/hep.30119. Epub 2018 Oct 13.
    • Case report
    • Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    • Li M, Mou Y, Hou S, Cao D, Li A.
    • Medicine (Baltimore). 2018 Nov;97(45):e13113. doi: 10.1097/MD.0000000000013113.
    • Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.
    • Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.
    • Int J Mol Sci. 2018 Oct 19;19(10). pii: E3249. doi: 10.3390/ijms19103249.
    • Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    • Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S.
    • BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
    • Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    • Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.
    • Br J Cancer. 2018 Oct 15. doi: 10.1038/s41416-018-0268-6. [Epub ahead of print]
    • BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
    • Piwocka K, Podszywałow-Bartnicka P, Skorski T.
    • Postepy Biochem. 2018 Oct 15;64(2):141-147.
    • [DNA damage repair: An emerging strategy in metastatic prostate cancer].
    • Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A.
    • Bull Cancer. 2018 Oct;105(10):944-954. doi: 10.1016/j.bulcan.2018.05.017. Epub 2018 Sep 29.
    • Review, [Article in French]
    • Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
    • Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.
    • Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
    • Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL.
    • Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.
    • BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
    • Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, Handorf EA, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N.
    • Cell Rep. 2018 Sep 25;24(13):3513-3527.e7. doi: 10.1016/j.celrep.2018.08.086.
    • Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report.
    • Cheng Y, Zhang J, Qin SK, Hua HQ.
    • Onco Targets Ther. 2018 Sep 18;11:5957-5962. doi: 10.2147/OTT.S176914. eCollection 2018.
    • Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
    • Shen JP, Ideker T.
    • J Mol Biol. 2018 Sep 14;430(18 Pt A):2900-2912. doi: 10.1016/j.jmb.2018.06.026. Epub 2018 Jun 20.
    • Role of PARP Inhibitors in BRCA-Related Malignancies.
    • Iqbal S, Rattu MA, Shah N.
    • US Pharm. 2018 Sep 14;9(43):HS10-HS16
    • Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
    • Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F.
    • Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018.
    • MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.
    • Plantamura I, Cosentino G, Cataldo A.
    • Front Oncol. 2018 Sep 3;8:352. doi: 10.3389/fonc.2018.00352. eCollection 2018.
    • Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    • Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.
    • Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216.
    • PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    • Konstantinopoulos PA, Matulonis UA.
    • Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
    • Commentary, Review

    Review:

    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.

    • FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    • Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.
    • Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.
    • Review

    Commentary, Review:

    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.

    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
    • Rescigno P, Chandler R, de Bono J.
    • Curr Opin Support Palliat Care. 2018 Sep;12(3):339-343. doi: 10.1097/SPC.0000000000000358.
    • Review
    • Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
    • Di Nunno V, Santoni M, Massari F.
    • Lancet Oncol. 2018 Sep;19(9):e437-e438. doi: 10.1016/S1470-2045(18)30458-3.

    Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

    Letter, Reply: Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? – Authors' reply (Lancet Oncology)

    • Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
    • Ashworth A, Lord CJ.
    • Nat Rev Clin Oncol. 2018 Sep;15(9):564-576. doi: 10.1038/s41571-018-0055-6.
    • Review
    • Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions.
    • Reilly SW, Puentes LN, Hsieh CJ, Makvandi M, Mach RH.
    • ACS Omega. 2018 Aug 31;3(8):9997-10001. doi: 10.1021/acsomega.8b00896. Epub 2018 Aug 28.
    • Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents.
    • Ingham MA, McGuinness JE, Kalinsky K, Schwartz GK.
    • JCO Precis Oncol. 2018 Nov [2018 Aug 18];2:1-6. doi: 10.1200/PO.18.00131.
    • The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
    • Guo XX, Wu HL, Shi HY, Su L, Zhang X.
    • Cancer Manag Res. 2018 Aug 10;10:2553-2562. doi: 10.2147/CMAR.S169558. eCollection 2018.
    • Advances in the use of PARP inhibitor therapy for breast cancer.
    • McCann KE, Hurvitz SA.
    • Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.
    • Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    • Frank S, Nelson P, Vasioukhin V.
    • F1000Res. 2018 Aug 2;7. pii: F1000 Faculty Rev-1173. doi: 10.12688/f1000research.14499.1. eCollection 2018.
    • Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
    • Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V4, Vivancos A.
    • J Natl Cancer Inst. 2018 Aug 1;110(8):914-917. doi: 10.1093/jnci/djy012.
    • BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
    • Ahmadzadehfar H, Gaertner F, Lossin PS1, Schwarz B, Essler M.
    • Clin Nucl Med. 2018 Aug;43(8):609-610. doi: 10.1097/RLU.0000000000002141.
    • Case report
    • Niraparib for the treatment of ovarian cancer.
    • Essel KG, Moore KN.
    • Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2.
    • Review
    • Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    • Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.
    • Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.
    • Case report
    • DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    • Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ.
    • J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.
    • Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    • Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.
    • Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
    • PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    • Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X.
    • J Exp Clin Cancer Res. 2018 Jul 16;37(1):153. doi: 10.1186/s13046-018-0810-7.
    • Using PARP Inhibitors in Advanced Ovarian Cancer.
    • O'Cearbhaill RE.
    • Oncology (Williston Park). 2018 Jul 15;32(7). pii: 614793.
    • Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
    • Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.
    • Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z.
    • Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
    • Minchom A, Aversa C, Lopez J.
    • Ther Adv Med Oncol. 2018 Jul 13;10:1758835918786658. doi: 10.1177/1758835918786658. eCollection 2018.
    • Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.
    • Chanez B, Chaffanet M, Adélaide J, Thomassin J, Garnier S, Carbuccia N, Guille A, Charrier N, Brenot-Rossi I, Walz J, Pignot G, Pakradouni J, Gonçalvès A, Eisinger F, Bertucci F, Birnbaum D, Gravis G.
    • JCO Precis Oncol. 2018 Jul 10;2018. doi: 10.1200/PO.18.00083. Epub 2018 Jul 10.
    • Case report
    • Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    • Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.
    • Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.
    • BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    • Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    • Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
    • An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    • Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer HN, Lyons JF, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.
    • Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.
    • Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    • Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R.
    • Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD.
    • J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085.
    • Review
    • BRCA1/2 testing: therapeutic implications for breast cancer management.
    • Tung NM, Garber JE.
    • Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5.
    • Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    • Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F.
    • Mol Cancer Res. 2018 Jul;16(7):1092-1102. doi: 10.1158/1541-7786.MCR-18-0106. Epub 2018 Mar 28.
    • A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
    • Trenner A, Godau J, Sartori AA.
    • Mol Cancer Ther. 2018 Jul;17(7):1392-1404. doi: 10.1158/1535-7163.MCT-17-1156. Epub 2018 Apr 13.
    • Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
    • Novohradsky V, Zajac J, Vrana O, Kasparkova J, Brabec V.
    • Oncotarget. 2018 Jun 19;9(47):28456-28473. doi: 10.18632/oncotarget.25466. eCollection 2018 Jun 19.
    • Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    • Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.
    • Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.
    • Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    • Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie D, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.
    • Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.
    • Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
    • Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.
    • Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.
    • Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
    • Necchi A, Raggi D, Giannatempo P, Alessi A, Serafini G, Colecchia M, Ali SM, Chung JH.
    • Eur J Cancer. 2018 Jun;96:128-130. doi: 10.1016/j.ejca.2018.03.021. Epub 2018 Apr 18.
    • Case report, Letter
    • The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    • Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.
    • Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.
    • Heat-induced BRCA2 degradation in human tumors provides rationale for hyperthermia-PARP-inhibitor combination therapies.
    • van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, van Gent D, Hardillo J, Verduijn G, Drooger J, van Rhoon G, Smedts D, van Doorn H, Boormans J, Jager A, Franckena M, Kanaar R.
    • Int J Hyperthermia. 2018 Jun;34(4):407-414. doi: 10.1080/02656736.2017.1355487. Epub 2017 Jul 31.
    • Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition.
    • Fang P, Madden JA, Neums L, Moulder RK, Forrest ML, Chien J.
    • Mol Cancer Res. 2018 Jun;16(6):961-973. doi: 10.1158/1541-7786.MCR-17-0607. Epub 2018 Mar 15.
    • APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
    • Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB.
    • Mol Cancer Ther. 2018 Jun;17(6):1167-1176. doi: 10.1158/1535-7163.MCT-17-0834. Epub 2018 Apr 6.
    • Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response.
    • Gorthi A, Bishop AJR.
    • Mol Cell Oncol. 2018 May 29;5(4):e1465014. doi: 10.1080/23723556.2018.1465014. eCollection 2018.

    EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

    • Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
    • Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):65-77. doi: 10.1200/EDBK_200715.
    • The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
    • Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH, Hussein UK, Zhang Z, Park HS, Park BH, Moon WS, Kim JR, Jang KY.
    • J Exp Clin Cancer Res. 2018 May 21;37(1):107. doi: 10.1186/s13046-018-0772-9.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD.
    • J Natl Cancer Inst. 2018 May 18. doi: 10.1093/jnci/djy085. [Epub ahead of print]
    • Review
    • BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
    • Ahmadzadehfar H, Gaertner F, Lossin PS, Schwarz B, Essler M.
    • Clin Nucl Med. 2018 May 14. doi: 10.1097/RLU.0000000000002141. [Epub ahead of print]
    • Case report
    • Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
    • Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.
    • Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.
    • Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, Typas D, Lammers M, Mailand N, Nussenzweig A, Lukas J, Choudhary C.
    • Cell. 2018 May 3;173(4):972-988.e23. doi: 10.1016/j.cell.2018.03.050. Epub 2018 Apr 12.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    • Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P.
    • Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23.
    • Review
    • PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    • Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H.
    • Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7.
    • Update on PARP Inhibitors in Breast Cancer.
    • Zimmer AS, Gillard M, Lipkowitz S, Lee JM.
    • Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2.
    • Review
    • Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
    • Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.
    • Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.
    • IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.
    • Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway HE, Mukherjee S, Sekeres MA, van Noorden CJF, Maciejewski JP.
    • Clin Cancer Res. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16.
    • PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
    • Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J, Li S.
    • Cancer Med. 2018 Apr;7(4):1285-1296. doi: 10.1002/cam4.1318. Epub 2018 Feb 26.
    • Crosstalk of DNA double-strand break repair pathways in PARP inhibitor treatment of BRCA1/2-mutated Cancer.
    • Sunada S, Nakanishi A, Miki Y.
    • Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6.
    • [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
    • Shimodaira H.
    • Gan To Kagaku Ryoho. 2018 Apr;45(4):587-592.
    • Review, [Article in Japanese]
    • PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    • Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W.
    • Oncol Rep. 2018 Apr;39(4):1901-1909. doi: 10.3892/or.2018.6238. Epub 2018 Jan 26.
    • Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.
    • Colombo I, Lheureux S, Oza AM.
    • Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018.
    • Beyond PARP—POLθ as an anticancer target.
    • Higgins GS, Boulton SJ.
    • Science. 2018 Mar 16;359(6381):1217-1218. doi: 10.1126/science.aar5149.
    • Review
    • EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
    • Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.
    • Nature. 2018 Mar 15;555(7696):387-391. doi: 10.1038/nature25748. Epub 2018 Mar 7.

    Research news:

    Ewing Sarcomas Phenocopy BRCA1-Deficient Tumors.

    • BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
    • Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.
    • Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.
    • Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
    • Carvajal R, Fernández J, García N, López A, Gutiérrez-Enríquez S, Diez O, Benítez J, Salinas M, Teulé A, Brunet J, Radice P, Peterlongo P, Schindler D, Huertas P, Puente XS, Lázaro C, Pujana MÀ, Surrallés J.
    • Nat Commun. 2018 Mar 6;9(1):967. doi: 10.1038/s41467-018-03433-3.
    • Inherited DNA-Repair Defects in Colorectal Cancer.
    • AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T, Mu XJ, Nishihara R, Qian Z, Liu L, Yurgelun MB, Syngal S, Garraway LA, Ogino S, Fuchs CS, Van Allen EM.
    • Am J Hum Genet. 2018 Mar 1;102(3):401-414. doi: 10.1016/j.ajhg.2018.01.018. Epub 2018 Feb 22.
    • A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    • Shah AP, Patel CN, Sureja DK, Sanghavi KP.
    • Folia Med (Plovdiv). 2018 Mar 1;60(1):39-47. doi: 10.1515/folmed-2017-0067.
    • Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
    • Chen CC, Feng W, Lim PX, Kass EM, Jasin M.
    • Annu Rev Cancer Biol. 2018 Mar;2:313-336. doi: 10.1146/annurev-cancerbio-030617-050502. Epub 2017 Dec 1.
    • Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    • Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    • Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
    • Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
    • Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.
    • The NCI-MATCH trial and precision medicine in gynecologic cancers.
    • Barroilhet L, Matulonis U.
    • Gynecol Oncol. 2018 Mar;148(3):585-590. doi: 10.1016/j.ygyno.2018.01.008. Epub 2018 Feb 1.
    • Review
    • Management of the toxicities of common targeted therapeutics for gynecologic cancers.
    • Gunderson CC, Matulonis U, Moore KN.
    • Gynecol Oncol. 2018 Mar;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010. Epub 2018 Feb 1.
    • Review
    • MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.
    • Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D.
    • Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20.
    • A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
    • Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred JB, Lensing JL, Chen A, Ji JJ, Zhang Y, Erlichman C, Haluska P, Kaufmann SH.
    • Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.
    • Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    • Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, Soper JT, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.
    • Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.
    • Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.
    • Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ.
    • JCO Precis Oncol. 2018;2:PO.17.00176. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.

    Commentary:

    Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    • Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.
    • Ganesan S.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-4. doi: 10.1200/PO.18.00001.

    Case report:

    Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    Original research:

    Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

    • Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage.
    • Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I.
    • Oncotarget. 2018 Jan 24;9(12):10585-10605. doi: 10.18632/oncotarget.24291. eCollection 2018 Feb 13.
    • MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    • Xie B, Yuan Z, Yang Y, Sun Z, Zhou S, Fang X.
    • Breast Cancer Res Treat. 2018 Feb 10. doi: 10.1007/s10549-018-4708-z. [Epub ahead of print]
    • Database report
    • Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
    • Chen X, Huan X, Liu Q, Wang Y, He Q, Tan C, Chen Y, Ding J, Xu Y, Miao Z, Yang C.
    • Eur J Med Chem. 2018 Feb 10;145:389-403. doi: 10.1016/j.ejmech.2018.01.018. Epub 2018 Jan 8.
    • Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    • Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.
    • Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.
    • Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    • Anampa J, Chen A, Wright J, Patel M, Pellegrino C, Fehn K, Sparano JA, Andreopoulou E.
    • Clin Breast Cancer. 2018 Feb;18(1):e135-e142. doi: 10.1016/j.clbc.2017.08.013. Epub 2017 Sep 1.
    • Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    • McCann KE.
    • Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428.
    • Review
    • The development of PARP as a successful target for cancer therapy.
    • Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.
    • Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26.
    • Review
    • BRCA1 gene: function and deficiency.
    • Takaoka M, Miki Y.
    • Int J Clin Oncol. 2018 Feb;23(1):36-44. doi: 10.1007/s10147-017-1182-2. Epub 2017 Sep 7.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    • Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H.
    • Oncogene. 2018 Jan 18;37(3):341-351. doi: 10.1038/onc.2017.326. Epub 2017 Sep 25.
    • EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    • Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC.
    • Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.
    • Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    • Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.
    • Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
    • Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    • Lee A, Djamgoz MBA.
    • Cancer Treat Rev. 2018 Jan;62:110-122. doi: 10.1016/j.ctrv.2017.11.003. Epub 2017 Nov 13.
    • Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    • Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.
    • Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.
    • DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    • Misenko SM, Patel DS, Her J, Bunting SF.
    • Cell Cycle. 2018;17(7):881-891. doi: 10.1080/15384101.2018.1456295. Epub 2018 May 15.
    • PARP Inhibitor Drugs In The Treatment Of Breast, Ovarian, Prostate And Pancreatic Cancers: An Update of Clinical Trials.
    • Kamel D, Gray C, Walia J, Kumar V.
    • Curr Drug Targets. 2018;19(1):21-37. doi: 10.2174/1389450118666170711151518.
    • PARP Inhibitors for the Treatment of Ovarian Cancer.
    • Cortesi L, Toss A, Cucinotto I.
    • Curr Cancer Drug Targets. 2018;18(9):877-893. doi: 10.2174/1568009618666180308104646.
    • Review
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
    • Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.
    • Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
    • Schmitt A, Feldmann G, Zander T, Reinhardt HC.
    • Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.
    • Olaparib.
    • Bochum S, Berger S, Martens UM.
    • Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
    • Review
    • BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    • Okuma HS, Yonemori K.
    • Adv Exp Med Biol. 2017 [2017 Dec 28];1026:271-286. doi: 10.1007/978-981-10-6020-5_13.
    • Review
    • Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
    • Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.
    • Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.
    • Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.
    • Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N.
    • Oncotarget. 2017 Sep 28;8(69):113418-113430. doi: 10.18632/oncotarget.21300. eCollection 2017 Dec 26.
    • BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    • Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.
    • Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.
    • Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.
    • Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM.
    • Oncotarget. 2017 Oct 31;8(67):111026-111040. doi: 10.18632/oncotarget.22195. eCollection 2017 Dec 19.
    • Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
    • Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ.
    • Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12.
    • Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2-ovarian cancers.
    • Bueno R, Mar JC.
    • Methods. 2017 Dec 1;131:74-82. doi: 10.1016/j.ymeth.2017.07.021. Epub 2017 Jul 25.
    • Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.
    • Su C, Gius JP, Van Steenberg J, Haskins AH, Heishima K, Omata C, Iwayama M, Murakami M, Mori T, Maruo K, Kato TA.
    • Sci Rep. 2017 Dec 1;7(1):16704. doi: 10.1038/s41598-017-16795-3.
    • Directing the use of DDR kinase inhibitors in cancer treatment.
    • Brandsma I, Fleuren EDG, Williamson CT, Lord CJ.
    • Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14.
    • Review
    • PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    • Bitler BG, Watson ZL, Wheeler LJ, Behbakht K.
    • Gynecol Oncol. 2017 Dec;147(3):695-704. doi: 10.1016/j.ygyno.2017.10.003. Epub 2017 Oct 14.
    • Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
    • O'Kane GM, Connor AA, Gallinger S.
    • Trends Mol Med. 2017 Dec;23(12):1121-1137. doi: 10.1016/j.molmed.2017.10.007. Epub 2017 Nov 10.
    • Review
    • PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
    • Sisay M, Edessa D.
    • Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017.
    • PARP inhibition causes premature loss of cohesion in cancer cells.
    • Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.
    • Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • The HSF1-PARP13-PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis.
    • Fujimoto M, Takii R, Takaki E, Katiyar A, Nakato R, Shirahige K, Nakai A.
    • Nat Commun. 2017 Nov 21;8(1):1638. doi: 10.1038/s41467-017-01807-7.
    • The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    • Hromas R, Kim HS, Sidhu G, Williamson E, Jaiswal A, Totterdale TA, Nole J, Lee SH, Nickoloff JA, Kong KY./li>
    • Breast Cancer Res. 2017 Nov 16;19(1):122. doi: 10.1186/s13058-017-0912-8.
    • Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.
    • Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J.
    • Clin Cancer Res. 2017 Nov 15;23(22):6875-6887. doi: 10.1158/1078-0432.CCR-17-0593. Epub 2017 Aug 22.
    • Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    • Garber J.
    • OncoTherapy Network. 2017 Nov 15.
    • The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
    • Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S.
    • Oncol Res. 2017 Nov 2;25(9):1441-1451. doi: 10.3727/096504017X14926854178616. Epub 2017 Apr 20.
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Review, Conference abstract
    • Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors.
    • Dhawan MS, Bartelink IH, Aggarwal R, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser MM, Kelley RK, Maktabi T, Thomas S, Munster PN.
    • Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8.
    • A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    • Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.
    • Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.
    • Drugging the Cancers Addicted to DNA Repair.
    • Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R.
    • J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx059.
    • Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    • Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J.
    • J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx062.
    • Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
    • Chen WH, Song SS, Qi MH, Huan XJ, Wang YQ, Jiang H, Ding J, Ren GB, Miao ZH, Li J.
    • Acta Pharmacol Sin. 2017 Nov;38(11):1521-1532. doi: 10.1038/aps.2017.104. Epub 2017 Aug 3.
    • Treatment of recurrent ovarian cancer.
    • Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F.
    • Ann Oncol. 2017 Nov;28 Suppl 8:viii51-viii56. doi: 10.1093/annonc/mdx441.
    • Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    • Gadducci A, Guerrieri ME.
    • Anticancer Res. 2017 Nov;37(11):5955-5965.
    • Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.
    • Mihailidou C, Karamouzis MV, Schizas D, Papavassiliou AG.
    • Biochimie. 2017 Nov;142:135-143. doi: 10.1016/j.biochi.2017.09.001. Epub 2017 Sep 7.
    • Review
    • Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
    • Kawahara N, Ogawa K, Nagayasu M, Kimura M, Sasaki Y, Kobayashi H.
    • Biomed Rep. 2017 Nov;7(5):391-399. doi: 10.3892/br.2017.990. Epub 2017 Sep 27.
    • [Prostate cancer and DNA repair genes].
    • Penel N.
    • Bull Cancer. 2017 Nov;104(11):958-961. doi: 10.1016/j.bulcan.2017.07.005. Epub 2017 Oct 9.
    • Letter, [Article in French]
    • [Impairment of DNA damage response and cancer].
    • Rancoule C, Vallard A, Guy JB, Espenel S, Sauvaigo S, Rodriguez-Lafrasse C, Magné N.
    • Bull Cancer. 2017 Nov;104(11):962-970. doi: 10.1016/j.bulcan.2017.09.006. Epub 2017 Nov 11.
    • Review, [Article in French]
    • [Abnormalities of DNA repair and gynecological cancers].
    • Auguste A, Leary A.
    • Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18.
    • Review, [Article in French]
    • [DNA repair as a therapeutic target].
    • Eberst L, Brahmi M, Cassier PA.
    • Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11.
    • Review, [Article in French]
    • Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    • Johnson N, Liao JB.
    • Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S14-S19. doi: 10.1097/IGC.0000000000001115.
    • Conference report
    • Homologous Recombination Deficiency in Breast Cancer: A Clinical Review.
    • den Brok WD, Schrader KA, Sun S, Tinker AV, Zhao EY, Aparicio S, Gelmon KA.
    • JCO Precis Oncol. 2017 Nov;1:1-13. doi: 10.1200/PO.16.00031.
    • Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition.
    • Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, Klempner SJ.
    • JCO Precis Oncol. 2017 Nov;1:1-7. doi: 10.1200/PO.17.00043.
    • BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma.
    • Irani S, Bidari-Zerehpoush F.
    • J Int Soc Prev Community Dent. 2017 Nov;7(Suppl 3):S155-S162. doi: 10.4103/jispcd.JISPCD_184_17. Epub 2017 Nov 30.
    • TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
    • Abo MA, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.
    • Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.
    • EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
    • Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD.
    • Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.
    • A Novel Use for Olaparib for Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    • Martin GA, Chen AH, Parikh K.
    • Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.
    • Review
    • Doubling Down on BRCA-Mutated Cancer.
    • Wahner Hendrickson AE, Kaufmann SH, Swisher EM.
    • Trends Cancer. 2017 Nov;3(11):743-744. doi: 10.1016/j.trecan.2017.09.005. Epub 2017 Sep 29.
    • Review
    • Never tear us a-PARP: Dealing with DNA lesions during mitosis.
    • Schoonen PM, van Vugt MATM.
    • Mol Cell Oncol. 2017 Oct 31;5(1):e1382670. doi: 10.1080/23723556.2017.1382670. eCollection 2018.
    • PARPi focus the spotlight on replication fork protection in cancer.
    • Schlacher K.
    • Nat Cell Biol. 2017 Oct 31;19(11):1309-1310. doi: 10.1038/ncb3638.
    • Research news, Review
    • Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
    • Ohmoto A, Yachida S.
    • Onco Targets Ther. 2017 Oct 26;10:5195-5208. doi: 10.2147/OTT.S139336. eCollection 2017.
    • Combining Enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
    • Thompson TC, Li L, Broom BM.
    • Oncotarget. 2017 Oct 25. doi: 10.18632/oncotarget.22074. [Epub ahead of print]
    • The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells.
    • Bourton EC, Ahorner PA, Plowman PN, Zahir SA, Al-Ali H, Parris CN.
    • J Cancer. 2017 Oct 23;8(19):4048-4056. doi: 10.7150/jca.21338. eCollection 2017.
    • Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
    • Falchi F, Giacomini E, Masini T, Boutard N, Di Ianni L, Manerba M, Farabegoli F, Rossini L, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Pellicciari R, Roberti M, Cavalli A.
    • ACS Chem Biol. 2017 Oct 20;12(10):2491-2497. doi: 10.1021/acschembio.7b00707. Epub 2017 Sep 1.
    • FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2.
    • Porro A, Berti M, Pizzolato J, Bologna S, Kaden S, Saxer A, Ma Y, Nagasawa K, Sartori AA, Jiricny J.
    • Nat Commun. 2017 Oct 20;8(1):1073. doi: 10.1038/s41467-017-01074-6.
    • Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
    • Osoegawa A, Gills JJ, Kawabata S, Dennis PA.
    • Oncotarget. 2017 Jul 28;8(50):87044-87053. doi: 10.18632/oncotarget.19667. eCollection 2017 Oct 20.
    • Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    • Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.
    • Eur Urol Focus. 2017 Oct 19. pii: S2405-4569(17)30238-9. doi: 10.1016/j.euf.2017.10.001. [Epub ahead of print]
    • Review
    • Mitigating Side Effects to Reach PARP Inhibitors' Potential.
    • Markman M.
    • Medscape. News & Perspective. 2017 Oct 13.
    • Role of PARP Inhibitors in Triple-Negative Breast Cancer.
    • Azvolinsky A, Garber J.
    • OncoTherapy Network. 2017 Oct 4.
    • The HRD decision--which PARP inhibitor to use for whom and when.
    • Kohn EC, Lee JM, Ivy SP.
    • Clin Cancer Res. 2017 Oct 3. doi: 10.1158/1078-0432.CCR-17-2186. [Epub ahead of print]
    • Review
    • Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
    • Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.
    • Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.
    • SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.
    • Cairns J, Ingle JN, Wickerham LD, Weinshilboum R, Liu M, Wang L.
    • PLoS Genet. 2017 Oct 2;13(10):e1007031. doi: 10.1371/journal.pgen.1007031. eCollection 2017 Oct.
    • Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    • Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, Jones D, George TJ Jr, Hromas R.
    • Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867. doi: 10.1007/s00280-017-3401-y. Epub 2017 Jul 29.
    • Thwarting endogenous stress: BRCA protects against aldehyde toxicity.
    • Ray Chaudhuri A, Nussenzweig A.
    • EMBO Mol Med. 2017 Oct;9(10):1331-1333. doi: 10.15252/emmm.201708194.
    • A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.
    • Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC.
    • Mol Cancer Ther. 2017 Oct;16(10):2058-2068. doi: 10.1158/1535-7163.MCT-16-0660. Epub 2017 Jun 27.
    • BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
    • Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.
    • Tumour Biol. 2017 Oct;39(10):1010428317727479. doi: 10.1177/1010428317727479.
    • Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    • Chen W, Guo N, Qi M, Dai H, Hong M, Guan L, Huan X, Song S, He J, Wang Y, Xi Y, Yang X, Shen Y, Su Y, Sun Y, Gao Y, Chen Y, Ding J, Tang Y, Ren G, Miao Z, Li J.
    • Eur J Med Chem. 2017 Sep 29;138:514-531. doi: 10.1016/j.ejmech.2017.06.053. Epub 2017 Jun 27.
    • Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.
    • Hengel SR, Spies MA, Spies M.
    • Cell Chem Biol. 2017 Sep 21;24(9):1101-1119. doi: 10.1016/j.chembiol.2017.08.027.
    • Review
    • More breast cancer patients could benefit from PARP inhibitors.
    • [No author given]
    • Cancer. 2017 Sep 15;123(18):3433. doi: 10.1002/cncr.30962.
    • Research news
    • The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    • Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML.
    • Cancer. 2017 Sep 15;123(18):3532-3539. doi: 10.1002/cncr.30808. Epub 2017 Jun 13.

    Editorial:

    Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-Mutated prostate cancers.

    • Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.
    • Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.
    • Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.
    • Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
    • Hoang LN, Gilks BC.
    • Adv Anat Pathol. 2017 Sep 13. doi: 10.1097/PAP.0000000000000177. [Epub ahead of print]
    • Review
    • Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    • Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.
    • Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.
    • Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
    • Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS.
    • Cancer Biol Ther. 2017 Sep 2;18(9):694-704. doi: 10.1080/15384047.2017.1364323. Epub 2017 Sep 8.
    • Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells.
    • Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD.
    • Biotechnol Bioeng. 2017 Sep;114(9):2085-2095. doi: 10.1002/bit.26293. Epub 2017 May 18.
    • Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
    • Domchek SM.
    • Cancer Discov. 2017 Sep;7(9):937-939. doi: 10.1158/2159-8290.CD-17-0734.
    • Review

    Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.

    Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

    Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

    • Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
    • Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.
    • Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
    • Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Nava Rodrigues D, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS.
    • Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.

    Research news:

    New blood test could extend prostate cancer survival.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    Press: New three-in-one blood test opens door to precision medicine for prostate cancer. (MedicalXpress)

    • Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
    • Babiker HM, McBride A, Cooke LS, Mahadevan D.
    • Expert Opin Investig Drugs. 2017 Sep;26(9):1063-1072. doi: 10.1080/13543784.2017.1360275. Epub 2017 Jul 30.
    • Review
    • Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
    • Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.
    • Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.
    • Niraparib in ovarian cancer: results to date and clinical potential.
    • Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F.
    • Ther Adv Med Oncol. 2017 Sep;9(9):579-588. doi: 10.1177/1758834017718775. Epub 2017 Jul 12.
    • The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    • Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.
    • Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.
    • Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.
    • Lim JSJ, Tan DSP.
    • Cancers (Basel). 2017 Aug 22;9(8). pii: E109. doi: 10.3390/cancers9080109.
    • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    • Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.
    • Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
    • Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.
    • Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD.
    • Cancer Res. 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.
    • A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    • Senhaji Mouhri Z, Goodfellow E, Jean-Claude B.
    • BMC Cancer. 2017 Aug 11;17(1):540. doi: 10.1186/s12885-017-3504-1.
    • Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
    • Yuan Z, Chen S, Sun Q, Wang N, Li D, Miao S, Gao C, Chen Y, Tan C, Jiang Y.
    • Bioorg Med Chem. 2017 Aug 1;25(15):4100-4109. doi: 10.1016/j.bmc.2017.05.058. Epub 2017 May 31.
    • A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
    • Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.
    • Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.
    • Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
    • Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH.
    • J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7.
    • IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
    • Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T.
    • Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20.
    • Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
    • Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.
    • Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.
    • Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    • Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S.
    • Oncotarget. 2017 Jul 25;8(30):48794-48806. doi: 10.18632/oncotarget.10720.
    • Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
    • Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM.
    • Nat Commun. 2017 Jul 17;8:15981. doi: 10.1038/ncomms15981.
    • Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    • Piacente F, Caffa I, Ravera S, Sociali G, Passalacqua M, Vellone VG, Becherini P, Reverberi D, Monacelli F, Ballestrero A, Odetti P, Cagnetta A, Cea M, Nahimana A, Duchosal MA, Bruzzone S, Nencioni A.
    • Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
    • PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    • Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC.
    • Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. Epub 2017 Feb 6.
    • Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.
    • Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, Habrand JL, Saintigny Y, Joly F.
    • Oncotarget. 2017 Jul 7;8(40):69105-69124. doi: 10.18632/oncotarget.19079. eCollection 2017 Sep 15.
    • Epistasis in genomic and survival data of cancer patients.
    • Matlak D, Szczurek E.
    • PLoS Comput Biol. 2017 Jul 5;13(7):e1005626. doi: 10.1371/journal.pcbi.1005626. [Epub ahead of print]
    • Olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer.
    • Yarchoan M, Myzak MC, Johnson Iii BA, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.
    • Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.
    • The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
    • van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, Kanaar R.
    • Oncotarget. 2017 Jul 4;8(27):44593-44604. doi: 10.18632/oncotarget.17861.
    • Development of PARP inhibitors in gynecological malignancies.
    • Ang YLE, Tan DSP.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14.
    • Review
    • Relevance of DNA damage repair in the management of prostate cancer.
    • Banks P, Xu W, Murphy D, James P, Sandhu S.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):287-301. doi: 10.1016/j.currproblcancer.2017.06.001. Epub 2017 Jun 27.
    • Review
    • Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    • Yang ZM, Liao XM, Chen Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Ding J, Zhang A, He JX, Miao ZH.
    • Acta Pharmacol Sin. 2017 Jul;38(7):1038-1047. doi: 10.1038/aps.2017.8. Epub 2017 Apr 17.
    • Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
    • Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.
    • Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.
    • Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
    • Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.
    • JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.
    • Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    • Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.
    • J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.
    • Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
    • van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S.
    • Mol Cancer Ther. 2017 Jul;16(7):1279-1289. doi: 10.1158/1535-7163.MCT-16-0740. Epub 2017 May 12.
    • Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
    • Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M.
    • Oncologist. 2017 Jul;22(7):804-810. doi: 10.1634/theoncologist.2016-0415. Epub 2017 May 9.
    • BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.
    • Mayor P, Gay LM, Lele S, Elvin JA.
    • Gynecol Oncol Rep. 2017 Jun 21;21:57-60. doi: 10.1016/j.gore.2017.06.010. eCollection 2017 Aug.
    • Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
    • Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.
    • Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.
    • Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
    • de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.
    • Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.
    • OlympiAD: Olaparib Captures Gold for BRCA-Mutated Breast Cancer Patients.
    • Miller KD, Domchek SM.
    • Medscape. Coverage from the ASCO 2017 Annual Meeting. 2017 Jun 12.
    • Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
    • Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    • Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.
    • The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    • Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ.
    • Cancer. 2017 Jun 1;123(11):1912-1924. doi: 10.1002/cncr.30631. Epub 2017 Mar 21.
    • Review
    • Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
    • Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JCY, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.
    • J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • Analysis Suggests Wider Use for PARP Inhibitors.
    • [No authors listed]
    • Cancer Discov. 2017 Jun;7(6):OF7. doi: 10.1158/2159-8290.CD-NB2017-049. Epub 2017 Apr 12.
    • News
    • PARP Inhibitors in Prostate Cancer.
    • Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK.
    • Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2.
    • Review
    • Niraparib: First Global Approval.
    • Scott LJ.
    • Drugs. 2017 Jun;77(9):1029-1034. doi: 10.1007/s40265-017-0752-y.
    • Review
    • Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    • Talens F, Jalving M, Gietema JA, van Vugt MATM.
    • Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2.
    • Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    • Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F.
    • Invest New Drugs. 2017 Jun;35(3):251-259. doi: 10.1007/s10637-016-0424-x. Epub 2017 Jan 23.
    • Truncating Titin (TTN) Variants in Chemotherapy-Induced Cardiomyopathy.
    • Linschoten M, Teske AJ, Baas AF, Vink A, Dooijes D, Baars HF, Asselbergs FW.
    • J Card Fail. 2017 Jun;23(6):476-479. doi: 10.1016/j.cardfail.2017.03.003. Epub 2017 Mar 14.
    • Case report
    • Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.
    • Verdaguer H, Saurí T, Macarulla T.
    • J Gastrointest Oncol. 2017 Jun;8(3):405-417. doi: 10.21037/jgo.2016.11.15.
    • Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.
    • Parkes A, Arun BK, Litton JK.
    • Oncologist. 2017 Jun;22(6):655-666. doi: 10.1634/theoncologist.2016-0430. Epub 2017 May 3.
    • Review
    • Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
    • Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.
    • Sci Transl Med. 2017 May 31;9(392). pii: eaal5148. doi: 10.1126/scitranslmed.aal5148.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    • Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.
    • Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.
    • Salvati E, Botta L, Amato J, Di Leva FS, Zizza P, Gioiello A, Pagano B, Graziani G, Tarsounas M, Randazzo A, Novellino E, Biroccio A, Cosconati S.
    • J Med Chem. 2017 May 11;60(9):3626-3635. doi: 10.1021/acs.jmedchem.6b01563. Epub 2017 May 1.
    • Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    • Romero-Laorden N, Piñeiro-Yañez E, Gutierrez-Pecharroman A, Pacheco MI, Calvo E, Al-Shahrour F, Castro E, Olmos D1.
    • Ann Oncol. 2017 May 1;28(5):1158-1159. doi: 10.1093/annonc/mdx067.
    • Letter, Case report
    • Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    • Oei AL, van Leeuwen CM, Ahire VR, Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJA, Crezee J, Kok HP, Krawczyk PM, Kanaar R, Franken NAP.
    • Oncotarget. 2017 Apr 25;8(17):28116-28124. doi: 10.18632/oncotarget.15922.
    • Germline mutations in pancreatic cancer and potential new therapeutic options.
    • Pihlak R, Valle JW, McNamara MG.
    • Oncotarget. 2017 Apr 20;8(42):73240-73257. doi: 10.18632/oncotarget.17291. eCollection 2017 Sep 22.
    • PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    • Rivero JD, Kohn EC.
    • Oncology (Williston Park). 2017 Apr 15;31(4). pii: 221995.
    • Review
    • BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    • Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.
    • Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.
    • Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    • Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.
    • Elife. 2017 Apr 11;6. pii: e21350. doi: 10.7554/eLife.21350.
    • Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    • Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.
    • J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.
    • PARP Inhibitors for Cancer Therapy.
    • Lin KY, Kraus WL.
    • Cell. 2017 Apr 6;169(2):183. doi: 10.1016/j.cell.2017.03.034.
    • Review
    • "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
    • Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A.
    • Oncotarget. 2017 Apr 4;8(14):23891-23904. doi: 10.18632/oncotarget.14409.
    • Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
    • Smith LD, Leme de Calais F, Raponi M, Mellone M, Buratti E, Blaydes JP, Baralle D.
    • Int J Cancer. 2017 Apr 1;140(7):1564-1570. doi: 10.1002/ijc.30574. Epub 2017 Jan 30.
    • Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
    • Gravells P, Grant E, Smith KM, James DI, Bryant HE.
    • DNA Repair (Amst). 2017 Apr;52:81-91. doi: 10.1016/j.dnarep.2017.02.010. Epub 2017 Feb 17.
    • Rucaparib: First Global Approval.
    • Syed YY.
    • Drugs. 2017 Apr;77(5):585-592. doi: 10.1007/s40265-017-0716-2.
    • Review
    • Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
    • Vaishampayan UN.
    • Curr Opin Oncol. 2017 Mar 18. doi: 10.1097/CCO.0000000000000370. [Epub ahead of print]
    • Review
    • PARP inhibitors: Synthetic lethality in the clinic.
    • Lord CJ, Ashworth A.
    • Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
    • Review
    • Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.
    • McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY.
    • NPJ Syst Biol Appl. 2017 Mar 6;3:8. doi: 10.1038/s41540-017-0011-6. eCollection 2017.
    • BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.
    • Lips EH, Debipersad R, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.
    • Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.
    • Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    • De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C.
    • Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.
    • Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    • Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.
    • Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.
    • Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss.
    • Ding X, Sharan SK.
    • Transl Cancer Res. 2017 Mar;6(Suppl 2):S441-S442. doi: 10.21037/tcr.2017.03.42.

    Commentary: Turning the concept of synthetic lethality on its head. (Translational Cancer Research)

    Original Research:

    Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.

    • CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
    • Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J, Kabeer F, Lai D, Soriano P, Banáth J, Chiu DS, Yap D, Le DD, Ye FB, Zhang A, Thu K, Soong J, Lin SC, Tsai AH, Osako T, Algara T, Saunders DN, Wong J, Xian J, Bally MB, Brenton JD, Brown GW, Shah SP, Cescon D, Mak TW, Caldas C, Stirling PC, Hieter P, Balasubramanian S, Aparicio S.
    • Nat Commun. 2017 Feb 17;8:14432. doi: 10.1038/ncomms14432.
    • Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
    • Goodfellow E, Senhaji Mouhri Z, Williams C, Jean-Claude BJ.
    • Bioorg Med Chem Lett. 2017 Feb 1;27(3):688-694. doi: 10.1016/j.bmcl.2016.09.054. Epub 2016 Sep 22.
    • Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    • Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M.
    • Cancer Lett. 2017 Feb 1;386:131-140. doi: 10.1016/j.canlet.2016.11.021. Epub 2016 Nov 25.
    • ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    • Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L.
    • Genes Dev. 2017 Feb 1;31(3):318-332. doi: 10.1101/gad.290957.116. Epub 2017 Feb 27.
    • Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
    • De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, Denys H.
    • Acta Clin Belg. 2017 Feb;72(1):6-11. doi: 10.1080/17843286.2016.1188455. Epub 2016 May 31.
    • Review
    • PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.
    • Sander Effron S, Makvandi M, Lin L, Xu K, Li S, Lee H, Hou C, Pryma DA, Koch C, Mach RH.
    • Cancer Biother Radiopharm. 2017 Feb;32(1):9-15. doi: 10.1089/cbr.2016.2133. Epub 2017 Jan 24.
    • PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
    • O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH.
    • Drugs. 2017 Feb;77(2):113-130. doi: 10.1007/s40265-016-0688-7.
    • Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated disease.
    • Killock D.
    • Nat Rev Clin Oncol. 2017 Feb;14(2):71. doi: 10.1038/nrclinonc.2016.207. Epub 2016 Dec 13.
    • Research Highlight
    • MLN4924 suppresses the BRCA1 complex and synergizes with PARP1 inhibition in NSCLC cells.
    • Guo ZP, Hu YC, Xie Y, Jin F, Song ZQ, Liu XD, Ma T, Zhou PK.
    • Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. doi: 10.1016/j.bbrc.2016.12.162. Epub 2016 Dec 26.
    • The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
    • Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E.
    • Int J Mol Sci. 2017 Jan 20;18(1). pii: E210. doi: 10.3390/ijms18010210.
    • RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    • Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha MS, Liu S.
    • Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.
    • Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    • Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.
    • BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.
    • PARP inhibition in BRCA2-mutated prostate cancer.
    • Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.
    • Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445.
    • Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
    • Brown JS, O'Carrigan B, Jackson SP, Yap TA.
    • Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21.
    • Review
    • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    • Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.
    • Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

    Comment:

    Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?

    • Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.
    • Williams DT, Staples CJ.
    • Adv Exp Med Biol. 2017;1007:1-16. doi: 10.1007/978-3-319-60733-7_1.
    • Review
    • Synthetic Lethal Interactions in Cancer Therapy.
    • Geng X, Wang X, Zhu D, Ying S.
    • Curr Cancer Drug Targets. 2017;17(4):304-310. doi: 10.2174/1568009616666160426122736.
    • Review
    • Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
    • Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC.
    • Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948.
    • Molecular Tests for the Choice of Cancer Therapy.
    • Sokolenko AP, Imyanitov EN.
    • Curr Pharm Des. 2017;23(32):4794-4806. doi: 10.2174/1381612823666170719110125.
    • Review
    • SABCS 2016: systemic therapy for metastatic breast cancer.
    • Gampenrieder SP, Rinnerthaler G, Greil R.
    • Memo. 2017;10(2):86-89. doi: 10.1007/s12254-017-0326-4. Epub 2017 Apr 4.
    • Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays.
    • Na Z, Pan S, Uttamchandani M, Yao SQ.
    • Methods Mol Biol. 2017;1518:139-156.
    • Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    • Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.
    • PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.
    • Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.
    • Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A.
    • Hum Mol Genet. 2016 Dec 15;25(24):5287-5299. doi: 10.1093/hmg/ddw343.
    • Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.
    • Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT.
    • World J Gastroenterol. 2016 Dec 14;22(46):10254-10259. doi: 10.3748/wjg.v22.i46.10254.
    • PARP inhibitor combination therapy.
    • Dréan A, Lord CJ, Ashworth A.
    • Crit Rev Oncol Hematol. 2016 Dec;108:73-85. doi: 10.1016/j.critrevonc.2016.10.010. Epub 2016 Oct 31.
    • PARP inhibitors and stratified treatment of prostate cancer.
    • Lavery A, Gilson C, Chowdhury S.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215. Epub 2016 Oct 17.
    • Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.
    • Anderson RC, Makvandi M, Xu K, Lieberman BP, Zeng C, Pryma DA, Mach RH.
    • Nucl Med Biol. 2016 Dec;43(12):752-758. doi: 10.1016/j.nucmedbio.2016.08.007. Epub 2016 Aug 12.
    • PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.
    • Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A.
    • Prz Menopauzalny. 2016 Dec;15(4):215-219. doi: 10.5114/pm.2016.65667. Epub 2017 Feb 8.
    • Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    • Cerrato A, Morra F, Celetti A.
    • J Exp Clin Cancer Res. 2016 Nov 24;35(1):179.
    • Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    • Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y.
    • Oncotarget. 2016 Nov 22;7(47):76534-76550. doi: 10.18632/oncotarget.12266.
    • Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
    • Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, Slifker M, Renner C, Chernoff J, Arias-Romero LE.
    • Oncotarget. 2016 Nov 22;7(47):76590-76603. doi: 10.18632/oncotarget.12576.
    • An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    • Wang YQ, Wang PY, Wang YT, Yang GF, Zhang A, Miao ZH.
    • J Med Chem. 2016 Nov 10;59(21):9575-9598. Epub 2016 Jul 27.
    • Review
    • LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.
    • Wang YS, Chen J, Cui F, Wang H, Wang S, Hang W, Zeng Q, Quan CS, Zhai YX, Wang JW, Shen XF, Jian YP, Zhao RX, Werle KD, Cui R, Liang J, Li YL, Xu ZX.
    • Oncotarget. 2016 Nov 8;7(45):73389-73401. doi: 10.18632/oncotarget.12334.
    • Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    • Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    • Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15.
    • Review
    • Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
    • Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA.
    • EMBO Rep. 2016 Nov;17(11):1609-1623. Epub 2016 Sep 5.
    • Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    • Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.
    • BMC Cancer. 2016 Oct 19;16(1):811.
    • The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
    • Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.
    • Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.
    • The current status of PARP inhibitors in ovarian cancer.
    • McLachlan J, George A, Banerjee S.
    • Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
    • Review
    • Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    • Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV.
    • Cancer Cell. 2016 Oct 10;30(4):637-650. doi: 10.1016/j.ccell.2016.09.002.
    • Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.
    • Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.
    • Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10.
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • Defects in homologous recombination repair behind the human diseases: FA and HBOC.
    • Katsuki Y, Takata M.
    • Endocr Relat Cancer. 2016 Oct;23(10):T19-T37. Epub 2016 Aug 22.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Synthetic lethality: the road to novel therapies for breast cancer.
    • Dhillon KK, Bajrami I, Taniguchi T, Lord C.
    • Endocr Relat Cancer. 2016 Oct;23(10):T39-T55. Epub 2016 Aug 15.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    • Buonerba C, Di Lorenzo G, Sonpavde G.
    • Expert Rev Mol Diagn. 2016 Oct;16(10):1113-1120. Epub 2016 Sep 28.
    • Review
    • PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment.
    • Zhao L, So CW.
    • Exp Hematol. 2016 Oct;44(10):902-7. doi: 10.1016/j.exphem.2016.07.007. Epub 2016 Jul 26.
    • Review
    • Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
    • Teo MY, O'Reilly EM.
    • J Gastrointest Oncol. 2016 Oct;7(5):738-749.
    • Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
    • Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF.
    • Radiat Res. 2016 Oct;186(4):327-332. Epub 2016 Sep 2.
    • Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
    • Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G.
    • Target Oncol. 2016 Oct;11(5):569-577.
    • Review
    • Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    • Castro E, Mateo J, Olmos D, de Bono JS.
    • Cancer J. 2016 Sep/Oct;22(5):353-356.
    • Review
    • The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    • Miller RE, Ledermann JA.
    • Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11.
    • DNA damage response as a therapeutic target in gynaecological cancers.
    • Leary A, Auguste A, Mesnage S.
    • Curr Opin Oncol. 2016 Sep;28(5):404-11. doi: 10.1097/CCO.0000000000000320.
    • Review
    • Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
    • Ding X, Chaudhuri AR, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK
    • Nat Commun. 2016 Aug 8;7:12425. doi: 10.1038/ncomms12425.

    Letter:

    Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss.

    Commentary: Turning the concept of synthetic lethality on its head. (Translational Cancer Research)

    • Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.
    • Lemech CR, Williams R, Thompson SR, McCaughan B, Chin M.
    • BMC Res Notes. 2016 Aug 3;9(1):386. doi: 10.1186/s13104-016-2189-x.
    • A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.
    • Makvandi M, Xu K, Lieberman BP, Anderson RC, Sander Effron S, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH.
    • Cancer Res. 2016 Aug 1;76(15):4516-24. doi: 10.1158/0008-5472.CAN-16-0416. Epub 2016 Jun 3.
    • The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    • Miller RE, Ledermann JA.
    • Clin Adv Hematol Oncol. 2016 Aug;14(8):619-627.
    • Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    • Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    • Gynecol Oncol. 2016 Aug;142(2):323-31. doi: 10.1016/j.ygyno.2016.06.005. Epub 2016 Jun 16.
    • DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    • Dhawan M, Ryan CJ, Ashworth A.
    • Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.
    • Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
    • Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM.
    • Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8.
    • Replication fork stability confers chemoresistance in BRCA-deficient cells.
    • Chaudhuri AR, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.
    • Nature. 2016 Jul 20;535(7612):382-7. doi: 10.1038/nature18325.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: NCI press release on new mechanism for chemo resistance in HBOC

    Research News:

    Researchers Find New Chemoresistance Mechanism in BRCA-Deficient Tumors.

    News Release: Uncovering a new principle in chemotherapy resistance in breast cancer. (NIH)

    Press: Uncovering a new principle in chemotherapy resistance in breast cancer. (Science Daily)

    • PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
    • Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME.
    • PLoS One. 2016 Jul 18;11(7):e0159341. doi: 10.1371/journal.pone.0159341. eCollection 2016.
    • Synthetic Lethal Interactions in Cancer Therapy.
    • Geng X, Wang X, Zhu D1, Ying S.
    • Curr Cancer Drug Targets. 2016 Jul 5. [Epub ahead of print]
    • Review
    • DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    • Rabenau K, Hofstatter E.
    • Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.
    • Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    • Passeri D, Camaioni E, Liscio P, Sabbatini P, Ferri M, Carotti A, Giacchè N, Pellicciari R, Gioiello A, Macchiarulo A.
    • ChemMedChem. 2016 Jun 20;11(12):1219-26. doi: 10.1002/cmdc.201500391. Epub 2015 Oct 1.
    • Review
    • The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
    • Gao D, Herman JG, Guo M.
    • Oncotarget. 2016 Jun 14;7(24):37331-37346. doi: 10.18632/oncotarget.7949.
    • Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    • Lim D, Ngeow J.
    • Endocr Relat Cancer. 2016 Jun;23(6):R267-85. doi: 10.1530/ERC-16-0116. Epub 2016 May 25.
    • The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
    • Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N.
    • Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186.

    News: Preventing Drug Resistance in Patients With Germline BRCA1 Mutations. (OncoTherapy Network)

    • Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    • Kristeleit RS, Miller RE, Kohn EC.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):e259-e268. doi: 10.1200/EDBK_159086.
    • Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
    • Palmbos PL, Hussain MH.
    • Oncology (Williston Park). 2016 May;30(5). pii: 217036.

    Comment

    PARP Inhibition in Prostate Cancer: A Promising Approach.

    • Editorial: Inhibiting PARP as a Strategic Target in Cancer.
    • Zorn KK, Annunziata CM.
    • Front Oncol. 2016 Apr 15;6:91. doi: 10.3389/fonc.2016.00091. eCollection 2016.
    • Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine.
    • Nilov DK, Tararov VI, Kulikov AV, Zakharenko AL, Gushchina IV, Mikhailov SN, Lavrik OI, Švedas VK.
    • Acta Naturae. 2016 Apr-Jun;8(2):108-15.
    • Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    • Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S.
    • Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367.
    • Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
    • Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C.
    • J Natl Cancer Inst. 2016 Feb 4;108(7). pii: djv437. doi: 10.1093/jnci/djv437. Print 2016 Jul.
    • Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    • Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.
    • Nat Med. 2016 Feb;22(2):194-201. doi: 10.1038/nm.4032. Epub 2016 Jan 18.
    • Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
    • Murata S, Zhang C, Finch N, Zhang K, Campo L, Breuer EK.
    • Biomed Res Int. 2016;2016:2346585. doi: 10.1155/2016/2346585. Epub 2016 Aug 24.
    • PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention.
    • Zhu X, Ma X, Hu Y.
    • Curr Med Chem. 2016;23(17):1756-74.
    • Review
    • [Specific features of drug sensitivity of hereditary cancers].
    • Imyanitov EN.
    • Vopr Onkol. 2016;62(2):221-6.
    • Review, [Article in Russian]
    • Targeting the DNA Damage Response in Cancer.
    • O'Connor MJ.
    • Mol Cell. 2015 Nov 19;60(4):547-560. doi: 10.1016/j.molcel.2015.10.040.
    • Discussion: The Next Big Things in the BRCA World.
    • [No author given].
    • My Gene Counsel. 2015 Nov 4.
    • Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    • Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D.
    • Mol Cancer Res. 2015 Nov;13(11):1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T. Epub 2015 Jul 27.
    • Poly(ADP-Ribose) Mediates the BRCA2-Dependent Early DNA Damage Response.
    • Zhang F, Shi J, Bian C, Yu X.
    • Cell Rep. 2015 Oct 27;13(4):678-689. doi: 10.1016/j.celrep.2015.09.040. Epub 2015 Oct 17.
    • [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    • Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    • Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
    • Review, [Article in French]
    • Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    • Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.
    • Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.
    • Embracing synthetic lethality of novel anticancer therapies.
    • Kamal A, Shaik TB, Malik MS.
    • Expert Opin Drug Discov. 2015 Oct;10(10):1119-32. doi: 10.1517/17460441.2015.1072167. Epub 2015 Jul 27.
    • Review
    • [Cancer therapy by PARP inhibitors].
    • Seimiya H.
    • Nihon Rinsho. 2015 Aug;73(8):1330-5.
    • Review, [Article in Japanese]
    • Profile of veliparib and its potential in the treatment of solid tumors.
    • Wagner LM.
    • Onco Targets Ther. 2015 Jul 29;8:1931-9. doi: 10.2147/OTT.S69935. eCollection 2015.
    • PARP inhibitors and more.
    • Bose CK, Basu N.
    • J Turk Ger Gynecol Assoc. 2015 Jun 1;16(2):107-10. doi: 10.5152/jtgga.2015.15029. eCollection 2015.
    • Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
    • Rolfo C, Swaisland H, Leunen K, Rutten A, Soetekouw P, Slater S, Verheul HM, Fielding A, So K, Bannister W, Dean E.
    • Adv Ther. 2015 Jun;32(6):510-22. doi: 10.1007/s12325-015-0214-4. Epub 2015 Jun 6.
    • The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
    • Li M, Yu X.
    • Oncogene. 2015 Jun;34(26):3349-56. doi: 10.1038/onc.2014.295. Epub 2014 Sep 15.
    • Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
    • Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.
    • Oncotarget. 2015 May 10;6(13):10746-58.
    • Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
    • Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY.
    • Oncotarget. 2015 May 10;6(13):11575-84.
    • Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
    • Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ.
    • Biomark Res. 2015 May 1;3:9. doi: 10.1186/s40364-015-0033-4. eCollection 2015.
    • PARP inhibitors: A new era of targeted therapy.
    • Tangutoori S, Baldwin P, Sridhar S.
    • Maturitas. 2015 May;81(1):5-9. doi: 10.1016/j.maturitas.2015.01.015. Epub 2015 Feb 7.
    • Review
    • Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
    • Jones P, Wilcoxen K, Rowley M, Toniatti C.
    • J Med Chem. 2015 Apr 23;58(8):3302-14. doi: 10.1021/jm5018237. Epub 2015 Mar 11.
    • Poly (adp-ribose) polymerase inhibitors: recent advances and future development.
    • Scott CL, Swisher EM, Kaufmann SH.
    • J Clin Oncol. 2015 Apr 20;33(12):1397-406. doi: 10.1200/JCO.2014.58.8848. Epub 2015 Mar 16.
    • Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
    • Lombardi AJ, Hoskins EE, Foglesong GD, Wikenheiser-Brokamp KA, Wiesmüller L, Hanenberg H, Andreassen PR, Jacobs AJ, Olson SB, Keeble WW, Hays LE, Wells SI.
    • Clin Cancer Res. 2015 Apr 15;21(8):1962-72. doi: 10.1158/1078-0432.CCR-14-2616. Epub 2015 Jan 21.
    • An update on PARP inhibitors for the treatment of cancer.
    • Benafif S, Hall M.
    • Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
    • DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
    • Stoepker C, Faramarz A, Rooimans MA, van Mil SE, Balk JA, Velleuer E, Ameziane N, Te Riele H, de Winter JP.
    • DNA Repair (Amst). 2015 Feb;26:54-64. doi: 10.1016/j.dnarep.2014.12.003. Epub 2014 Dec 24.
    • Olaparib: first global approval.
    • Deeks ED.
    • Drugs. 2015 Feb;75(2):231-40. doi: 10.1007/s40265-015-0345-6.
    • Review
    • PARP inhibitors.
    • Anwar M, Aslam HM, Anwar S.
    • Hered Cancer Clin Pract. 2015 Jan 17;13(1):4. doi: 10.1186/s13053-014-0024-8. eCollection 2015.
    • Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors.
    • Lord CJ, Tutt AN, Ashworth A.
    • Annu Rev Med. [2015 Jan;]66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.
    • Review
    • Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
    • Somyajit K, Mishra A, Jameei A, Nagaraju G.
    • Carcinogenesis. 2015 Jan;36(1):13-24. doi: 10.1093/carcin/bgu211. Epub 2014 Oct 7.
    • An update on PARP inhibitors-moving to the adjuvant setting.
    • Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M.
    • Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7.
    • Review
    • Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
    • Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ.
    • Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27.
    • Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.
    • Buege M, Mahajan PB.
    • Rev Recent Clin Trials. 2015;10(4):326-39.
    • Review
    • Myriad, AbbVie Expand Tumor BRACAnalysis CDx Collaboration.
    • [No author given]
    • Clinical OMICs. 1(14):5. 2014 Nov 19.
    • Development of synthetic lethality anticancer therapeutics.
    • Fang B.
    • J Med Chem. 2014 Oct 9;57(19):7859-73. doi: 10.1021/jm500415t. Epub 2014 Jun 13.
    • Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    • Lupo B, Trusolino L.
    • Biochim Biophys Acta. 2014 Aug;1846(1):201-15. doi: 10.1016/j.bbcan.2014.07.004. Epub 2014 Jul 12.
    • Transcriptional roles of PARP1 in cancer.
    • Schiewer MJ, Knudsen KE.
    • Mol Cancer Res. 2014 Aug;12(8):1069-80. doi: 10.1158/1541-7786.MCR-13-0672. Epub 2014 Jun 10.
    • Predictive biomarkers for cancer therapy with PARP inhibitors.
    • Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G.
    • Oncogene. 2014 Jul 24;33(30):3894-907. doi: 10.1038/onc.2013.352. Epub 2013 Sep 16.
    • Review
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
    • O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    • Front Oncol. 2014 Feb 28;4:42. eCollection 2014.
    • PARP inhibitors for anticancer therapy.
    • Curtin N.
    • Biochem Soc Trans. 2014 Feb;42(1):82-8. doi: 10.1042/BST20130187.
    • Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer.
    • Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM.
    • Cancer Res. 2014 Jan 1;74(1):31-7. doi: 10.1158/0008-5472.CAN-13-1701. Epub 2013 Nov 4.
    • Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity.
    • Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.
    • Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
    • Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J, Boothman DA.
    • Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28.
    • A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors.
    • Singh SS, Sarma JA, Narasu L, Dayam R, Xu S, Neamati N.
    • Curr Top Med Chem. 2014;14(17):2020-30.
    • Review
    • Structural Implications for Selective Targeting of PARPs.
    • Steffen JD, Brody JR, Armen RS, Pascal JM.
    • Front Oncol. 2013 Dec 20;3:301. doi: 10.3389/fonc.2013.00301.
    • Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
    • Arbini AA, Guerra F, Greco M, Marra E, Gandee L, Xiao G, Lotan Y, Gasparre G, Hsieh JT, Moro L.
    • Oncogenesis. 2013 Dec 16;2:e82. doi: 10.1038/oncsis.2013.45.
    • Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    • Curtin NJ, Szabo C.
    • Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29.
    • Appraising iniparib, the PARP inhibitor that never was--what must we learn?
    • Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.
    • Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15.
    • Review
    • ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    • Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S.
    • J Exp Clin Cancer Res. 2013 Nov 19;32(1):95. doi: 10.1186/1756-9966-32-95.
    • PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
    • Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G.
    • Front Oncol. 2013 Nov 14;3:279. doi: 10.3389/fonc.2013.00279. eCollection 2013.
    • Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    • Ogiwara H, Ui A, Shiotani B, Zou L, Yasui A, Kohno T.
    • Carcinogenesis. 2013 Nov;34(11):2486-97. doi: 10.1093/carcin/bgt240. Epub 2013 Jul 3.
    • Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
    • Helleday T.
    • Curr Opin Oncol. 2013 Nov;25(6):609-14. doi: 10.1097/CCO.0000000000000016.
    • Review
    • The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
    • Reinbolt RE, Hays JL.
    • Front Oncol. 2013 Oct 1;3:237. doi: 10.3389/fonc.2013.00237.
    • BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency.
    • Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A.
    • Clin Cancer Res. 2013 Sep 15;19(18):5003-15. doi: 10.1158/1078-0432.CCR-13-1391. Epub 2013 Jul 23.
    • The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
    • De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH.
    • Front Oncol. 2013 Sep 11;3:228. doi: 10.3389/fonc.2013.00228.
    • Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
    • Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.
    • Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
    • Croset A, Cordelières FP, Berthault N, Buhler C, Sun JS, Quanz M, Dutreix M.
    • Nucleic Acids Res. 2013 Aug;41(15):7344-55. doi: 10.1093/nar/gkt522. Epub 2013 Jun 12.
    • G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells.
    • McLuckie KI, Di Antonio M, Zecchini H, Xian J, Caldas C, Krippendorff BF, Tannahill D, Lowe C, Balasubramanian S.
    • J Am Chem Soc. 2013 Jul 3;135(26):9640-3. doi: 10.1021/ja404868t. Epub 2013 Jun 25.
    • PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
    • Metzger MJ, Stoddard BL, Monnat RJ Jr.
    • DNA Repair (Amst). 2013 Jul;12(7):529-34. doi: 10.1016/j.dnarep.2013.04.004. Epub 2013 May 16.
    • PARP Inhibitor Research Update.
    • Susan Domchek.
    • FORCE. Be Empowered Webinars. 2013 Jun 27.
    • Promise for BRCA-defective cancers.
    • Nicola McCarthy.
    • Nature Reviews Cancer. 2013 Jun 24;13(7):439. doi:10.1038/nrc3552.
    • Conference report
    • PARP Inhibitors Hold Promise in Pancreas Cancer.
    • Eileen O'Reilly.
    • Medscape Medical News. Medscape Oncology. 2013 Annual Meeting of the American Society of Clinical Oncology. 2013 Jun 17.
    • From integrative genomics to therapeutic targets.
    • Natrajan R, Wilkerson P.
    • Cancer Res. 2013 Jun 15;73(12):3483-8. doi: 10.1158/0008-5472.CAN-12-4717. Epub 2013 Jun 5.
    • Identification of miRNA modulators to PARP inhibitor response.
    • Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A.
    • DNA Repair (Amst). 2013 Jun 1;12(6):394-402. doi: 10.1016/j.dnarep.2013.02.003. Epub 2013 Apr 6.
    • Poly(ADP-ribose) polymerase inhibitors as cancer therapy.
    • Hilton JF, Hadfield MJ, Tran MT, Shapiro GI.
    • Front Biosci (Landmark Ed). 2013 Jun 1;18:1392-406.
    • Review
    • Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
    • Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A.
    • Mol Oncol. 2013 Jun;7(3):308-22. doi: 10.1016/j.molonc.2012.10.002. Epub 2012 Oct 29.
    • Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.
    • Li M, Yu X.
    • Cancer Cell. 2013 May 13;23(5):693-704. doi: 10.1016/j.ccr.2013.03.025.
    w

    23680151 -->
    • DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.
    • Mladenov E, Magin S, Soni A, Iliakis G.
    • Front Oncol. 2013 May 10;3:113. doi: 10.3389/fonc.2013.00113. eCollection 2013.
    • Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
    • Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.
    • Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.
    • [Research progresses of the PARP inhibitors for the treatment of cancer].
    • He YJ, Liu RH, Ning CQ, Yu NF.
    • Yao Xue Xue Bao. 2013 May;48(5):655-60.
    • Review, [Article in Chinese]
    • Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors.
    • Ye N, Chen CH, Chen T, Song Z, He JX, Huan XJ, Song SS, Liu Q, Chen Y, Ding J, Xu Y, Miao ZH, Zhang A.
    • J Med Chem. 2013 Apr 11;56(7):2885-903. doi: 10.1021/jm301825t. Epub 2013 Mar 21.
    • The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
    • Davidson D, Wang Y, Aloyz R, Panasci L.
    • Invest New Drugs. 2013 Apr;31(2):461-8. doi: 10.1007/s10637-012-9886-7. Epub 2012 Oct 9.
    • BRCA-associated pancreatic cancer: the evolving management.
    • Leung K, Saif MW.
    • JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462.
    • Molecular Pathways: Targeting PARP in Cancer Treatment.
    • Do K, Chen AP.
    • Clin Cancer Res. 2013 Mar 1;19(5):977-84. doi: 10.1158/1078-0432.CCR-12-0163. Epub 2012 Dec 26.
    • Resistance to PARP-Inhibitors in Cancer Therapy.
    • Montoni A, Robu M, Pouliot E, Shah GM.
    • Front Pharmacol. 2013 Feb 27;4:18. doi: 10.3389/fphar.2013.00018. eCollection 2013.
    • Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
    • Shunkwiler L, Ferris G, Kunos C.
    • Int J Mol Sci. 2013 Feb 8;14(2):3773-85. doi: 10.3390/ijms14023773.
    • Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
    • Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.
    • J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.
    • PARP Inhibitors: Targeting the Right Patients.
    • Azvolinsky A.
    • J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
    • Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition.
    • Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, Danda N, Chen W, Sablina A.
    • Cancer Res. 2012 Dec 15;72(24):6414-24. doi: 10.1158/0008-5472.CAN-12-1667. Epub 2012 Oct 18.
    • Molecular pathways: understanding the role of rad52 in homologous recombination for therapeutic advancement.
    • Lok BH, Powell SN.
    • Clin Cancer Res. 2012 Dec 1;18(23):6400-6. doi: 10.1158/1078-0432.CCR-11-3150. Epub 2012 Oct 15.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.
    • Basu B, Sandhu SK, de Bono JS.
    • Drugs. 2012 Aug 20;72(12):1579-90. doi: 10.2165/11635510-000000000-00000.
    • Review
    • Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
    • Pessetto ZY, Yan Y, Bessho T, Natarajan A.
    • Breast Cancer Res Treat. 2012 Jul;134(2):511-7. doi: 10.1007/s10549-012-2079-4. Epub 2012 May 6.
    • The role of PARP1 in the DNA damage response and its application in tumor therapy.
    • Wang Z, Wang F, Tang T, Guo C.
    • Front Med. 2012 Jun;6(2):156-64. doi: 10.1007/s11684-012-0197-3. Epub 2012 Jun 3.
    • Review
    • Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.
    • Park SR, Chen A.
    • Hematol Oncol Clin North Am. 2012 Jun;26(3):649-70, ix. doi: 10.1016/j.hoc.2012.02.012.
    • [PARP inhibitors--theoretical basis and clinical application].
    • Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.
    • Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21.
    • Checkpoint control and cancer.
    • Medema RH, Macůrek L.
    • Oncogene. 2012 May 24;31(21):2601-13. doi: 10.1038/onc.2011.451. Epub 2011 Oct 3.
    • Review
    • Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.
    • Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A.
    • Curr Cancer Drug Targets. 2012 May;12(4):329-38.
    • Review
    • Targeting the DNA damage response in oncology: past, present and future perspectives.
    • Basu B, Yap TA, Molife LR, de Bono JS.
    • Curr Opin Oncol. 2012 May;24(3):316-24. doi: 10.1097/CCO.0b013e32835280c6.
    • Review
    • Defective homologous recombination in human cancers.
    • Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ.
    • Cancer Treat Rev. 2012 Apr;38(2):89-100. doi: 10.1016/j.ctrv.2011.04.015. Epub 2011 Jun 28.
    • Review
    • [Cellular functions of BRCA genes - from basic science to therapeutics].
    • Miki Y.
    • Gan To Kagaku Ryoho. 2012 Apr;39(4):498-501.
    • [Article in Japanese]
    • [Clinical development of PARP inhibitors].
    • Toyoda M, Minami H.
    • Gan To Kagaku Ryoho. 2012 Apr;39(4):519-24.
    • Review, [Article in Japanese]
    • Advances in using PARP inhibitors to treat cancer.
    • Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH.
    • BMC Med. 2012 Mar 9;10:25. doi: 10.1186/1741-7015-10-25.
    • Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
    • Fathers C, Drayton RM, Solovieva S, Bryant HE.
    • Cell Cycle. 2012 Mar 1;11(5):990-7. doi: 10.4161/cc.11.5.19482. Epub 2012 Mar 1.
    • Targeted therapy for brain tumours: role of PARP inhibitors.
    • Leonetti C, Biroccio A, Graziani G, Tentori L.
    • Curr Cancer Drug Targets. 2012 Mar;12(3):218-36.
    • Review
    • A snapshot of chemoresistance to PARP inhibitors.
    • Chiarugi A.
    • Trends Pharmacol Sci. 2012 Jan;33(1):42-8. doi: 10.1016/j.tips.2011.10.001. Epub 2011 Nov 4.
    • Review
    • Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
    • Lovato A, Panasci L, Witcher M.
    • Front Pharmacol. 2012;3:202. doi: 10.3389/fphar.2012.00202. Epub 2012 Dec 27.